stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) EPS (diluted)
Kymera Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$3.69, compared with −$2.98 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$3.62. Over the past ten years it has ranged from −$24.28 (fiscal 2019) to −$0.48 (fiscal 2018); the current reading is higher than 25% of that period. Kymera Therapeutics, Inc. ranks 404th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.69 | — |
| FY2024 | −$2.98 | — |
| FY2023 | −$2.52 | — |
| FY2022 | −$2.87 | — |
| FY2021 | −$2.09 | — |
| FY2020 | −$3.15 | — |
| FY2019 | −$24.28 | — |
| FY2018 | −$0.48 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.32 | — |
| Jun 2026 | −$0.62 | — |
| Mar 2026 | −$0.71 | — |
| Dec 2025 | −$0.97 | — |
| 24 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| TECH Bio-Techne Corp compare | $1.15 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| BMRN BioMarin Pharmaceutical Inc. compare | −$0.10 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| SMMT Summit Therapeutics PLC compare | −$1.12 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| KYMR Kymera Therapeutics, Inc. | −$3.62 |
| PCVX Vaxcyte, Inc. compare | −$7.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on KYMR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement